Organelle dysfunction in hepatitis C virus-associated steatosis: Anything to learn from nonalcoholic steatohepatitis?

Expert Review of Gastroenterology and Hepatology

Volumn 5, Issue 2, 2011, Pages 265-277

  Pattullo, Venessa ^a,b,c   Douglas, Mark W ^a,b   George, Jacob ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

hepatitis C; insulin resistance; mitochondria; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; oxidative stress; steatosis

Indexed keywords

ACYL COENZYME A DESATURASE 1; ALPHA TOCOPHEROL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATORVASTATIN; CARNITINE PALMITOYLTRANSFERASE I; FATTY ACID SYNTHASE; FIBROBLAST GROWTH FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIVER X RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; MICRORNA; PEGINTERFERON; PIOGLITAZONE; RIBAVIRIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

5' UNTRANSLATED REGION; CELL ORGANELLE; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; ESTERIFICATION; FATTY ACID OXIDATION; FATTY LIVER; GENETIC SUSCEPTIBILITY; GLUCOSE METABOLISM; GLYCOGEN SYNTHESIS; HEPATITIS C VIRUS; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIPOLYSIS; LIVER CIRRHOSIS; MOLECULAR DYNAMICS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATION; PATHOGENESIS; PHYSICAL ACTIVITY; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION;

ANIMALS; CARBOHYDRATE METABOLISM; CYTOKINES; FATTY LIVER; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MICE; MITOCHONDRIAL DISEASES; ORGANELLES; OXIDATIVE STRESS; RATS; REACTIVE OXYGEN SPECIES;

EID: 79954557009     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.11.12     Document Type: Review

References (123)

1. St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 50(1), 68-76 (2009).
2. Hebbard L, George J. The chicken or the egg: adipocytes and hepatic insulin resistance. Hepatology 51(3), 1076-1079 (2010).
3. Johnson NA, George J. Fitness versus fatness: moving beyond weight loss in nonalcoholic fatty liver disease. Hepatology 52(1), 370-381 (2010).
4. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37(5), 1202-1219 (2003). (Pubitemid 36538699)
5. Rubbia-Brandt L, Quadri R, Abid K et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J. Hepatol. 33(1), 106-115 (2000). (Pubitemid 30418941)
6. Hui JM, Kench J, Farrell GC et al. Genotype-specifc mechanisms for hepatic steatosis in chronic hepatitis C infection. J. Gastroenterol. Hepatol. 17(8), 873-881 (2002).
7. Chitturi S, Abeygunasekera S, Farrell GC et al. NASH and insulin resistance: insulin hypersecretion and specifc association with the insulin resistance syndrome. Hepatology 35(2), 373-379 (2002). (Pubitemid 34106377)
8. Sanyal AJ. Insulin resistance and tissue repair: a 'fato-logical' phenomenon. Gastroenterology 125(6), 1886-1889 (2003). (Pubitemid 37500454)
9. Foufelle F, Ferre P. New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem. J. 366(Pt 2), 377-391 (2002). (Pubitemid 35001682)
10. Denechaud PD, Girard J, Postic C. Carbohydrate responsive element binding protein and lipid homeostasis. Curr. Opin. Lipidol. 19(3), 301-306 (2008). (Pubitemid 351681558)
11. Anderson N, Borlak J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol. Rev. 60(3), 311-357 (2008).
12. Roden M, Price TB, Perseghin G et al. Mechanism of free fatty acid-induced insulin resistance in humans. J. Clin. Invest. 97(12), 2859-2865 (1996). (Pubitemid 26197099)
13. Sanyal AJ, Campbell-Sargent C, Mirshahi F et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120(5), 1183-1192 (2001). (Pubitemid 32246672)
14. Cheng Z, Guo S, Copps K et al. Foxo1 integrates insulin signaling with mitochondrial function in the liver. Nat Med. 15(11), 1307-1311 (2009).
15. Paterson JM, Morton NM, Fievet C et al. Metabolic syndrome without obesity: Hepatic overexpression of 11ß-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc. Natl Acad. Sci. USA 101(18), 7088-7093 (2004). (Pubitemid 38596447)
16. Serviddio G, Sastre J, Bellanti F, Vina J, Vendemiale G, Altomare E. Mitochondrial involvement in non-alcoholic steatohepatitis. Mol. Aspects Med. 29(1-2), 22-35 (2008). (Pubitemid 351312221)
17. Rector RS, Thyfault JP, Uptergrove GM et al. Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. J. Hepatol. 52(5), 727-736 (2010).
18. Caldwell SH, de Freitas LA, Park SH et al. Intramitochondrial crystalline inclusions in nonalcoholic steatohepatitis. Hepatology 49(6), 1888-1895 (2009).
19. Caldwell SH, Swerdlow RH, Khan EM et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J. Hepatol. 31(3), 430-434 (1999). (Pubitemid 29408724)
20. Perez-Carreras M, Del Hoyo P, Martin MA et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 38(4), 999-1007 (2003). (Pubitemid 37221683)
21. Chavin KD, Yang S, Lin HZ et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J. Biol. Chem. 274(9), 5692-5700 (1999). (Pubitemid 29109222)
22. Gao D, Wei C, Chen L, Huang J, Yang S, Diehl AM. Oxidative DNA damage and DNA repair enzyme expression are inversely related in murine models of fatty liver disease. Am. J. Physiol. Gastrointest Liver Physiol. 287(5), G1070-G1077 (2004). (Pubitemid 39423700)
23. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 52(2), 774-788 (2010).
24. Feldstein AE, Lopez R, Abu-Rajab Tamimi T et al. Mass spectrometric profling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J. Lipid Res. 51 (10), 3046-3054 (2010).
25. Hoehn KL, Salmon AB, Hohnen-Behrens C et al. Insulin resistance is a cellular antioxidant defense mechanism. Proc. Natl Acad. Sci. USA 106(42), 17787-17792 (2009).
26. Wang D, Wei Y, Pagliassotti MJ. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology 147(2), 943-951 (2006). (Pubitemid 43113013)
27. Colgan SM, Tang D, Werstuck GH, Austin RC. Endoplasmic reticulum stress causes the activation of sterol regulatory element binding protein-2. Int. J. Biochem. Cell Biol. 39(10), 1843-1851 (2007). (Pubitemid 47321345)
28. Kammoun HL, Chabanon H, Hainault I et al. GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. J. Clin. Invest 119(5), 1201-1215 (2009).
29. Pan M, Cederbaum AI, Zhang YL, Ginsberg HN, Williams KJ, Fisher EA. Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J. Clin. Invest 113(9), 1277-1287 (2004). (Pubitemid 39069927)
30. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 27(1), 128-133 (1998). (Pubitemid 28041545)
31. Chalasani N, Gorski JC, Asghar MS et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 37(3), 544-550 (2003). (Pubitemid 36258775)
32. Singh R, Wang Y, Schattenberg JM, Xiang Y, Czaja MJ. Chronic oxidative stress sensitizes hepatocytes to death from 4-hydroxynonenal by JNK/c-Jun overactivation. Am. J. Physiol. Gastrointest Liver Physiol. 297(5), G907-G917 (2009).
33. Puri P, Mirshahi F, Cheung O et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology 134(2), 568-576 (2008). (Pubitemid 351173040)
34. Rutkowski DT, Wu J, Back SH et al. UPR pathways combine to prevent hepatic steatosis caused by ER stress-mediated suppression of transcriptional master regulators. Dev. Cell 15(6), 829-840 (2008).
35. Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 134(2), 424-431 (2008). (Pubitemid 351173050)
36. Fujita K, Nozaki Y, Wada K et al. Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology 50(3), 772-780 (2009).
37. Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 35(4), 898-904 (2002). (Pubitemid 34258385)
38. Shindo N, Fujisawa T, Sugimoto K et al. Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in novel spontaneous mouse model. J. Hepatol. 52(6), 903-912 (2010).
39. Namikawa C, Shu-Ping Z, Vyselaar JR et al. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J. Hepatol. 40(5), 781-786 (2004). (Pubitemid 38507358)
40. Dela Pena A, Leclercq I, Field J, George J, Jones B, Farrell G. NF-κB activation, rather than TNF, mediates hepatic infammation in a murine dietary model of steatohepatitis. Gastroenterology 129(5), 1663-1674 (2005). (Pubitemid 41597405)
41. Tomita K, Tamiya G, Ando S et al. Tumour necrosis factor α signalling through activation of Kupffer cells plays an essential role in liver fbrosis of non-alcoholic steatohepatitis in mice. Gut 55(3), 415-424 (2006). (Pubitemid 43268283)
42. Targher G, Bertolini L, Rodella S et al. Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin. Endocrinol. (Oxf) 64(6), 679-683 (2006). (Pubitemid 43775007)
43. Fukushima J, Kamada Y, Matsumoto H et al. Adiponectin prevents progression of steatohepatitis in mice by regulating oxidative stress and Kupffer cell phenotype polarization. Hepatol. Res. 39(7), 724-738 (2009).
44. Jin X, Ye YF, Chen SH, Yu CH, Liu J, Li YM. MicroRNA expression pattern in different stages of nonalcoholic fatty liver disease. Dig. Liver Dis. 41(4), 289-297 (2009).
45. Cheung O, Puri P, Eicken C et al. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology 48(6), 1810-1820 (2008).
46. Laplante M, Sabatini DM. An emerging role of mTOR in lipid biosynthesis. Curr. Biol. 19(22), R1046-R1052 (2009).
47. Calvert VS, Collantes R, Elariny H et al. A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology 46(1), 166-172 (2007). (Pubitemid 47171933)
48. Kubrusly MS, Correa-Giannella ML, Bellodi-Privato M et al. A role for mammalian target of rapamycin (mTOR) pathway in non alcoholic steatohepatitis related-cirrhosis. Histol. Histopathol. 25(9), 1123-1131 (2010).
49. Adams AC, Astapova I, Fisher FM et al. Thyroid hormone regulates hepatic expression of fbroblast growth factor 21 in a PPARα-dependent manner. J. Biol. Chem. 285(19), 14078-14082 (2010).
50. Dushay J, Chui PC, Gopalakrishnan GS et al. Increased fbroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 139(2), 456-463 (2010).
51. Li H, Fang Q, Gao F et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J. Hepatol. 53(5), 934-940 (2010).
52. Romeo S, Kozlitina J, Xing C et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 40(12), 1461-1465 (2008).
53. Hooper AJ, Adams LA, Burnett JR. Genetic determinants of hepatic steatosis in man. J. Lipid Res. DOI: 10.1194/jlr. R008896 (2011) (Epub ahead of print).
54. Petersen KF, Dufour S, Hariri A et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N. Engl. J. Med. 362(12), 1082-1089 (2010).
55. Abdelmalek MF, Suzuki A, Guy C et al. Increased fructose consumption is associated with fbrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 51(6), 1961-1971 (2010).
56. De Meijer VE, Le HD, Meisel JA et al. Dietary fat intake promotes the development of hepatic steatosis independently from excess caloric consumption in a murine model. Metabolism 59(8), 1092-1105 (2010).
57. Machado RM, Stefano JT, Oliveira CP et al. Intake of trans fatty acids causes nonalcoholic steatohepatitis and reduces adipose tissue fat content. J. Nutr. 140(6), 1127-1132 (2010).
58. Musso G, Gambino R, De Michieli F et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 37(4), 909-916 (2003). (Pubitemid 36397404)
59. Johnson NA, Stannard SR, Thompson MW. Muscle triglyceride and glycogen in endurance exercise: implications for performance. Sports Med. 34(3), 151-164 (2004). (Pubitemid 38338720)
60. Solomon TP, Haus JM, Marchetti CM, Stanley WC, Kirwan JP. Effects of exercise training and diet on lipid kinetics during free fatty acid-induced insulin resistance in older obese humans with impaired glucose tolerance. Am. J. Physiol. Endocrinol. Metab. 297(2), E552-E559 (2009).
61. Miele L, Valenza V, La Torre G et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49 (6), 1877-1887 (2009).
62. Begriche K, Massart J, Robin MA, Borgne-Sanchez A, Fromenty B. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J. Hepatol. 54(4), 773-794 (2011).
63. Hui JM, Sud A, Farrell GC et al. Insulin resistance is associated with chronic hepatitis C virus infection and fbrosis progression. Gastroenterology 125(6), 1695-1704 (2003). (Pubitemid 37500434)
64. Kawaguchi T, Ide T, Taniguchi E et al. Clearance of HCV improves insulin resistance, ß-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am. J. Gastroenterol. 102(3), 570-576 (2007). (Pubitemid 46328143)
65. Conjeevaram HS, Wahed AS, Afdhal N, Howell CD, Everhart JE, Hoofnagle JH. Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C Gastroenterology 140(2), 469-477 (2011).
66. Douglas MW, George J. Molecular mechanisms of insulin resistance in chronic hepatitis C World J. Gastroenterol. 15(35), 4356-4364 (2009).
67. Shintani Y, Fujie H, Miyoshi H et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 126(3), 840-848 (2004). (Pubitemid 38298332)
68. Milner KL, van der Poorten D, Trenell M et al. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology 138(3), 932-941.e1-3 (2010).
69. Kawaguchi T, Yoshida T, Harada M et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am. J. Pathol. 165(5), 1499-1508 (2004). (Pubitemid 39435150)
70. Pazienza V, Clement S, Pugnale P et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specifc mechanisms. Hepatology 45(5), 1164-1171 (2007). (Pubitemid 46775778)
71. Banerjee S, Saito K, Ait-Goughoulte M, Meyer K, Ray RB, Ray R. Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream Akt/protein kinase B signaling pathway for insulin resistance. J. Virol. 82(6), 2606-2612 (2008). (Pubitemid 351329151)
72. Banerjee A, Meyer K, Mazumdar B, Ray RB, Ray R. Hepatitis C virus differentially modulates activation of forkhead transcription factors and insulin-induced metabolic gene expression. J. Virol. 84(12), 5936-5946 (2010).
73. Bernsmeier C, Duong FH, Christen V et al. Virus induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C J. Hepatol. 49(3), 429-440 (2008).
74. Duong FH, Filipowicz M, Tripodi M, La Monica N, Heim MH. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology 126(1), 263-277 (2004). (Pubitemid 38040741)
75. Georgopoulou U, Tsitoura P, Kalamvoki M, Mavromara P. The protein phosphatase 2A represents a novel cellular target for hepatitis C virus NS5A protein. Biochimie 88(6), 651-662 (2006). (Pubitemid 44081829)
76. Christen V, Treves S, Duong FH, Heim MH. Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A. Hepatology 46(2), 558-565 (2007). (Pubitemid 47344792)
77. Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-κB. Proc. Natl Acad. Sci. USA 98(17), 9599-9604 (2001). (Pubitemid 32769349)
78. Korenaga M, Wang T, Li Y et al. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J. Biol. Chem. 280(45), 37481-37488 (2005). (Pubitemid 41642356)
79. Okuda M, Li K, Beard MR et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 122(2), 366-375 (2002). (Pubitemid 34116988)
80. Perlemuter G, Sabile A, Letteron P et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J. 16(2), 185-194 (2002). (Pubitemid 34113012)
81. Boulant S, Douglas MW, Moody L, Budkowska A, Targett-Adams P, McLauchlan J. Hepatitis C virus core protein induces lipid droplet redistribution in a microtubule-and dynein-dependent manner. Traffc 9(8), 1268-1282 (2008). (Pubitemid 352016286)
82. Abid K, Pazienza V, de Gottardi A et al. An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. J. Hepatol. 42(5), 744-751 (2005).
83. Hourioux C, Patient R, Morin A et al. The genotype 3-specifc hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model. Gut 56(9), 1302-1308 (2007). (Pubitemid 47300434)
84. Jhaveri R, McHutchison J, Patel K, Qiang G, Diehl AM. Specifc polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation. J. Infect. Dis., 197(2), 283-291 (2008). (Pubitemid 351263449)
85. Jhaveri R, Qiang G, Diehl AM. Domain 3 of hepatitis C virus core protein is suffcient for intracellular lipid accumulation. J. Infect. Dis., 200(11), 1781-1788 (2009).
86. Targett-Adams P, Boulant S, Douglas MW, McLauchlan J. Lipid metabolism and HCV infection. Viruses-Basel 2(5), 1195-1217 (2010).
87. Jackel-Cram C, Babiuk LA, Liu Q. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. J. Hepatol. 46(6), 999-1008 (2007). (Pubitemid 46669729)
88. Jackel-Cram C, Qiao L, Xiang Z et al. Hepatitis C virus genotype-3a core protein enhances sterol regulatory element-binding protein-1 activity through the phosphoinositide 3-kinase-Akt-2 pathway J. Gen. Virol. 91(Pt 6), 1388-1395 (2010).
89. Waris G, Felmlee DJ, Negro F, Siddiqui A. Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. J. Virol. 81(15), 8122-8130 (2007). (Pubitemid 47101498)
90. Moriishi K, Mochizuki R, Moriya K et al. Critical role of PA28γ in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc. Natl Acad. Sci. USA 104(5), 1661-1666 (2007). (Pubitemid 46214647)
91. Oem JK, Jackel-Cram C, Li YP et al. Activation of sterol regulatory element-binding protein 1c and fatty acid synthase transcription by hepatitis C virus non-structural protein 2. J. Gen Virol. 89(Pt 5), 1225-1230 (2008).
92. Park CY, Jun HJ, Wakita T, Cheong JH, Hwang SB. Hepatitis C virus nonstructural 4B protein modulates sterol regulatory element-binding protein signaling via the AKT pathway. J. Biol. Chem. 284(14), 9237-9246 (2009).
93. van der Poorten D, Shahidi M, Tay E et al. Hepatitis C virus induces the cannabinoid receptor 1. PLoS ONE 5(9), e12841 (2010).
94. Osei-Hyiaman D, DePetrillo M, Pacher P et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest., 115(5), 1298-1305 (2005). (Pubitemid 40629049)
95. Hezode C, Zafrani ES, Roudot-Thoraval F et al. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C Gastroenterology 134(2), 432-439 (2008). (Pubitemid 351173051)
96. Dharancy S, Malapel M, Perlemuter G et al. Impaired expression of the peroxisome proliferator-activated receptor α during hepatitis C virus infection. Gastroenterology 128(2), 334-342 (2005). (Pubitemid 40431087)
97. Tanaka N, Moriya K, Kiyosawa K, Koike K, Gonzalez FJ, Aoyama T PPARα activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J. Clin. Invest. 118(2), 683-694 (2008). (Pubitemid 351206557)
98. Tsutsumi T, Matsuda M, Aizaki H et al. Proteomics analysis of mitochondrial proteins reveals overexpression of a mitochondrial protein chaperon, prohibitin, in cells expressing hepatitis C virus core protein. Hepatology 50(2), 378-386 (2009).
99. Huang H, Sun F, Owen DM et al. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc. Natl Acad. Sci. USA 104(14), 5848-5853 (2007). (Pubitemid 47175622)
100. Mirandola S, Realdon S, Iqbal J et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 130(6), 1661-1669 (2006). (Pubitemid 43668848)
101. Zampino R, Ingrosso D, Durante-Mangoni E et al. Microsomal triglyceride transfer protein (MTP)-493G/T gene polymorphism contributes to fat liver accumulation in HCV genotype 3 infected patients. J. Viral Hepat. 15(10), 740-746 (2008).
102. Mirandola S, Osterreicher CH, Marcolongo M et al. Microsomal triglyceride transfer protein polymorphism (-493G/T) is associated with hepatic steatosis in patients with chronic hepatitis C Liver Int. 29(4), 557-565 (2009).
103. Petit JM, Minello A, Jooste V et al. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. J. Clin Endocrinol Metab 90(4), 2240-2243 (2005). (Pubitemid 40586268)
104. Cua IH, Hui JM, Bandara P et al. Insulin resistance and liver injury in hepatitis C is not associated with virus-specifc changes in adipocytokines. Hepatology 46 (1), 66-73 (2007). (Pubitemid 47171922)
105. Jopling CL. Regulation of hepatitis C virus by microRNA-122. Biochem. Soc. Trans., 36(Pt 6), 1220-1223 (2008).
106. Lanford RE, Hildebrandt-Eriksen ES, Petri A et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327(5962), 198-201 (2010).
107. Esau C, Davis S, Murray SF et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab., 3(2), 87-98 (2006).
108. Braconi C, Valeri N, Gasparini P et al. Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes. Clin. Cancer. Res. 16(3), 957-966 (2010).
109. Steuerwald NM, Parsons JC, Bennett K, Bates TC, Bonkovsky HL. Parallel microRNA and mRNA expression profling of (genotype 1b) human hepatoma cells expressing hepatitis C virus. Liver Int. 30(10), 1490-1504 (2010)
110. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med. 15(1), 31-33 (2009).
111. Pedersen IM, Cheng G, Wieland S et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 449(7164), 919-922 (2007). (Pubitemid 47598616)
112. Sarasin-Filipowicz M, Oakeley EJ, Duong FH et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl Acad. Sci. USA 105(19), 7034-7039 (2008). (Pubitemid 351754525)
113. Shaheen M, Echeverry D, Oblad MG, Montoya MI, Teklehaimanot S, Akhtar AJ. Hepatitis C, metabolic syndrome, and infammatory markers: results from the Third National Health and Nutrition Examination Survey [NHANES III]. Diabetes Res. Clin. Pract. 75(3), 320-326 (2007). (Pubitemid 46074212)
114. Belfort R, Harrison SA, Brown K et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl. J. Med. 355(22), 2297-2307 (2006). (Pubitemid 44837778)
115. Hirose A, Ono M, Saibara T et al. Angiotensin II type 1 receptor blocker inhibits fbrosis in rat nonalcoholic steatohepatitis. Hepatology 45 (6), 1375-1381 (2007). (Pubitemid 46918321)
116. Kawaguchi T, Nagao Y, Matsuoka H, Ide T, Sata M. Branched-chain amino acid-enriched supplementation improves insulin resistance in patients with chronic liver disease. Int J. Mol. Med. 22(1), 105-112 (2008).
117. Filippatos TD, Elisaf MS. Combination drug treatment in patients with non-alcoholic fatty liver disease. World J. Hepatol. 2(4), 139-142 (2010).
118. Sanyal AJ, Chalasani N, Kowdley KV et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl. J. Med. 362(18), 1675-1685 (2010).
119. Kimura Y, Hyogo H, Yamagishi S et al. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J. Gastroenterol. 45(7), 750-757 (2010).
120. Yoneda M, Fujita K, Nozaki Y et al. Effcacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: an open-label, pilot study. Hepatol. Res. 40(6), 613-621 (2010).
121. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 52(1), 79-104 (2010).
122. Romero-Gomez M, Diago M, Andrade RJ et al. Treatment of insulin resistance with metformin in naive genotype 1 chronic hepatitis C patients receiving PEGinterferon α-2a plus ribavirin. Hepatology 50(6), 1702-1708 (2009).
123. Khattab M, Emad M, Abdelaleem A et al. Pioglitazone improves virological response to PEGinterferon α-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int. 30(3), 447-454 (2010).